A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

  • Dev, Anouk (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/47863/SVHM-2018-161236(v2)
NMA SSA Reference Number: SSA/47863/MonH-2019-167981(v1)
Monash Health Ref: RES-19-0000-176X
Effective start/end date11/03/1910/03/24


  • clinical trial
  • treatment efficacy
  • liver cancer
  • phase 3 study